Vera Therapeutics Inc logo

VERA - Vera Therapeutics Inc Share Price

$18 0.0  0.0%

Last Trade - 30/07/21

Small Cap
Market Cap £274.3m
Enterprise Value £238.9m
Revenue £n/a
Position in Universe 3974th / 7015
Unlock VERA Revenue
Relative Strength (%)
1m +28.3%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -33.3%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000
Balance Sheet
FINANCIAL BRIEF: : For the three months ended 31 March 2021, VeraTherapeutics Inc revenues was not reported. Net losstotaled to $4.7M.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


VERA Revenue Unlock VERA Revenue

Net Income

VERA Net Income Unlock VERA Revenue

Normalised EPS

VERA Normalised EPS Unlock VERA Revenue

PE Ratio Range

VERA PE Ratio Range Unlock VERA Revenue

Dividend Yield Range

VERA Dividend Yield Range Unlock VERA Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
VERA EPS Forecasts Unlock VERA Revenue
Profile Summary

Vera Therapeutics, Inc. is a clinical stage biotechnology company. The Company is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a biologic inhibitor of B cells and plasma cells. Atacicept is self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. Atacicept is being developed for the treatment of immunoglobulin A nephropathy (IgAN), a rare autoimmune disease that can lead to dialysis, kidney transplant, serious disease and early death.

Last Annual December 31st, 2020
Last Interim March 31st, 2021
No. of Shareholders: n/a
No. of Employees: 12
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Market
Shares in Issue 21,277,614
Free Float (0.0%)
Eligible for
VERA Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for VERA
Upcoming Events for VERA
Frequently Asked Questions for Vera Therapeutics Inc
What is the Vera Therapeutics Inc share price?

As of 30/07/21, shares in Vera Therapeutics Inc are trading at $18, giving the company a market capitalisation of £274.3m. This share price information is delayed by 15 minutes.

How has the Vera Therapeutics Inc share price performed this year?

Shares in Vera Therapeutics Inc are currently trading at $18 and the price has moved by % over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Vera Therapeutics Inc price has moved by % over the past year.

What are the analyst and broker recommendations for Vera Therapeutics Inc?

There are no analysts currently covering Vera Therapeutics Inc.

When will Vera Therapeutics Inc next release its financial results?

Vera Therapeutics Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2022-03-31
What is the Vera Therapeutics Inc dividend yield?

Vera Therapeutics Inc does not currently pay a dividend.

Does Vera Therapeutics Inc pay a dividend?

Vera Therapeutics Inc does not currently pay a dividend.

When does Vera Therapeutics Inc next pay dividends?

Vera Therapeutics Inc does not currently pay a dividend.

How do I buy Vera Therapeutics Inc shares?

To buy shares in Vera Therapeutics Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Vera Therapeutics Inc?

Shares in Vera Therapeutics Inc are currently trading at $18, giving the company a market capitalisation of £274.3m.

Where are Vera Therapeutics Inc shares listed? Where are Vera Therapeutics Inc shares listed?

Here are the trading details for Vera Therapeutics Inc:

Country of listing: United States
Exchange: NMQ
Ticker Symbol: VERA
What kind of share is Vera Therapeutics Inc?

Based on an overall assessment of its quality, value and momentum, Vera Therapeutics Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Vera Therapeutics Inc share price forecast 2021?

Shares in Vera Therapeutics Inc are currently priced at $18. At that level they are trading at 44.44% discount to the analyst consensus target price of 0.00.

Analysts covering Vera Therapeutics Inc currently have a consensus Earnings Per Share (EPS) forecast of -2.495 for the next financial year.

How can I tell whether the Vera Therapeutics Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Vera Therapeutics Inc. Over the past six months, the relative strength of its shares against the market has been %. At the current price of $18, shares in Vera Therapeutics Inc are trading at 15.51% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Vera Therapeutics Inc PE Ratio?

We were not able to find PE ratio data for Vera Therapeutics Inc.

Who are the key directors of Vera Therapeutics Inc?

Vera Therapeutics Inc's management team is headed by:

Marshall Fordyce - CEO
Lauren Frenz - EXO
Joanne Curley - EXO
Tom Doan - SVP
Sean Grant - CFO
Who are the major shareholders of Vera Therapeutics Inc?

Here are the top five shareholders of Vera Therapeutics Inc based on the size of their shareholding:

Longitude Capital Management Co., LLC Venture Capital
Percentage owned: 14.77% (3.10m shares)
Fidelity Management & Research Company LLC Investment Advisor
Percentage owned: 14.65% (3.07m shares)
Abingworth Management Limited Venture Capital
Percentage owned: 14.12% (2.96m shares)
Sofinnova Venture Partners X, L.P. Individual Investor
Percentage owned: 13.9% (2.91m shares)
Citadel Advisors LLC Hedge Fund
Percentage owned: 9.66% (2.03m shares)
Similar to VERA
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.